Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2002

View Archived Issues

Novel HIV integrase inhibitors in early development at Shionogi

Taisho claims preparation and use of two series of VEGF antagonists

Urokinase inhibitors with utility in cancer covered by Pentapharm patent

Novel AGE-breaking agents prepared and tested at Torrent

New modulators of chemokine receptors under study at AstraZeneca

Pfizer announces approval of Lipitor for use in children

Altana researchers identify novel tryptase inhibitors for asthma and other respiratory disorders

New PDE5 inhibitors in early development at Pfizer

Merck scientists study antidiabetic biguanide compounds

Update of PVAC treatment program for psoriasis

Preclinical antitumor activity of the anti-CD80 antibody IDEC-114

Effects of new Na+ channel blocker in rat pain models

T-588 protects rats against facial motoneuron injury

Intrathecal CGX-1007 protects against ischemic brain injury with extended therapeutic window

Improvement in memory, hippocampal apoptosis in AD rats treated with ibudilast

Cannabis-based medicine advances to phase II trials in patients undergoing chemotherapy

New, orally active NS3 protease inhibitor effective and safe in patients with chronic HCV infection

Targeted Genetics presents promising preclinical data from hemophilia program

CRF1 antagonist assessed in animal models of anxiety and depression

Initiation of phase III trial of eptifibatide in heart attack

F-97013-GD: a potent, orally active atypical antipsychotic agent

Phase III clinical data demonstrate efficacy of RU-0211 in treating occasional constipation

Baxter to acquire Epic Therapeutics

Health Canada approves irbesartan for diabetic renal disease

Positive results from TA-1790 erectile dysfunction study

Safety study completed for inhaled form of epinephrine

Human interferon beta gene therapy with selective activity against RCC